| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	
																	CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35)...
																	
																	
																	
																	Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) models as well as a post-hoc...
																	HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $16 price tar...
																	CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.31)...
																	HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $16 price tar...